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Introduction
CRMO is a rare, orphan auto-inflammatory disease
characterized by recurrent episodes of pain associated
with sterile bone inflammation. There is no consensus
on the optimal treatment.
Objectives
The aim of this study was to review our CRMO patients
and report our results with etanercept treatment in
patients with a resistant course in CRMO.
Methods
Retrospective descriptive case series of nine children diag-
nosed as CRMO at the Department of Pediatric Rheuma-
tology at Hacettepe University, Ankara, Turkey. Disease
activity was assessed by acute phase reactants (ESR, CRP),
physician and patient/parent visual analogue scales (VAS)
(0-10 cm), and radiological findings (MRI and bone
scintigraphy).
Results
The median age of symptom onset was 8,2 years, while the
patients were diagnosed to have CRMO at a median of 10
years of age. Eight out of nine patients presented with
extremity pain, while five of the patients had back pain on
presentation. Eight out of nine patients presented with
extremity pain, while five had back pain on presentation.
The patients had a median of three lesions at the time of
diagnosis. There was sacroiliitis in seven patients. Four out
of nine patients were treated with nonsteroidal anti-
inflammatory drugs (NSAID) and methotrexate (MTX).
Five patients did not respond to these treatments, thus
etanercept therapy was started at an initial dose of 0,8 mg/
kg/week after a median of 24 months from diagnosis.
Acute phase reactants returned to normal, physician and
patient/parent visual analogue scales significantly
improved in all patients after etanercept treatment. We
were able to show healing of lesions in imaging that corre-
lated with the improvement of VAS and pain in the
patients, suggesting that anti-TNF was effective on the
bone inflammation. We have extended the time interval
between two doses of etanercept from one week to two
weeks after six months of remission with maintenance of
the complete response in four of these patients.
Conclusion
Our treatment policy in CRMO is to start with NSAIDs
and MTX. If the patient is refractory to these drugs, anti-
TNF treatment is commenced. Anti-TNF treatment was
effective in the treatment of our CRMO patients, We
suggest that extending the dosing interval is an effective
option once they are in remission for 6 months. We also
suggest that imaging may be included as an outcome mea-
sure in patients with CRMO. Further prospective studies
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